Immune cell study sheds light on childhood disease
NCT ID NCT02317133
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study examined blood samples from 100 children with Henoch Schönlein Purpura (HSP) and a control group to see if regulatory T cells (Tregs) are missing or not working properly. The goal was to learn more about the disease, not to test a new treatment. Researchers measured Treg levels, immune markers, and gut bacteria to find possible clues about HSP.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
100 people
The number who actually took part.
- Started
-
Feb 2015
- Finished
-
Jul 2017
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Three different populations will be included in this study: (A) patients presenting with an acute episode of Henoch Schönlein purpura; (B) patients who have had an episode of Henoch Schönlein purpura in the past, but currently present with no symptoms; (C) a group of control patients recruted from elective surgery candidates at the participating hospitals.
- Ages
-
3 to 17 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
General inclusion criteria for all sub-populations included in the study * The child (with age- and comprehension-skill-appropriate information) and parents (or persons exercising parental authority) have been informed about the implementation of the study, its objectives, constraints and patient rights * The child (depending on age) and parents (or persons exercising parental authority) have given their free and informed consent and signed the consent * The patient must be insured or beneficiary of a health insurance plan Inclusion criteria for population A: Henoch Schönlein purpura, acute episodes * The diagnosis of Henoch Schönlein purpura was made by a physician according to the EULAR / PRES / PRINTO 2010 criteria (purpura predominantly on the lower limbs associated with one of the following criteria: abdominal pain, arthralgia or arthritis, kidney damage or suggestive histology (immune deposits dominated by Immunoglobulin A (IgA)) * The patient is not treated via immunosuppression (steroids or other immunosuppressive / biotherapy) and has not been treated like this for at least 15 days Inclusion criteria for population B: Henoch Schönlein purpura in remission * The diagnosis of Henoch Schönlein purpura was made by a physician according to the EULAR / PRES / PRINTO 2010 criteria * The patient has has a Henoch Schönlein purpura episode in the past, and no longer has any symptoms of the disease * The patient is not treated via immunosuppression (steroids or other immunosuppressive / biotherapy) and has not been treated like this for at least 15 days Inclusion criteria for population C: controls * Subjects free from infectious, inflammatory or autoimmune diseases * Candidates for elective surgery (circumcision, urological surgery, removal of tonsils and adenoids) Exclusion Criteria: * The patient is participating in another interventional study or is in an exclusion period determined by a previous study * The child refuses to participate in the study * Parents (or persons with parental responsibility if any) refuse to sign the consent * It is impossible to correctly inform the patient or his/her parents (or persons with parental authority if any) * The patient has another inflammatory or autoimmune disease * Patient on immunosuppressive / biotherapy treatments
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Henoch-Schönlein purpura are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHRU de Montpellier - Hôpital Lapeyronie
Montpellier, 34295, France
-
CHRU de Nîmes - Hôpital Universitaire Carémeau
Nîmes, 30029, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.